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Human papillomaviruses (HPVs) have been recognized as etiologic factors in a variety of diseases. Due to the
large number of HPV types, methods for HPV genotyping are difficult to standardize. Despite this fact, several
methods exist, and some of them are available commercially. In this study, we evaluated the Roche Diagnostics
linear array (LA) HPV genotyping assay, the Innogenetics INNO-LiPA (line probe assay [LiPA]), and two non-
commercial reverse line blot (RLB) assays based on either primers GP5 and GP6 (GP) or newly designed
broad-spectrum primers BSGP5 and BSGP6 (BS). The reliabilities of these assays were tested with a wide
spectrum of HPV types less prevalent in cervical samples. This is the first study to compare the performance of the
most widely used HPV genotyping methods with selected samples positive for low-prevalence HPV types. We focused
on interassay agreement, both overall and type specific, in cases with single and/or multiple HPV infections.
Interassay agreement was moderate in cases of single HPV infections and poor in cases of multiple HPV infections.
The LA and the BS-based RLB assays found a higher rate of cases positive for multiple HPV types than LiPA and
the GP-based RLB assay. The weakest capability in detecting multiple HPV infections was observed for LiPA. The
use of only one assay in epidemiological and clinical studies might lead to biased conclusions. Therefore, a
universally evaluated and agreed upon HPV typing assay or a combination of current assays is needed for possible
clinical applications, and knowledge of their limitations is advised.
Human papillomaviruses (HPVs) have been recognized as
etiologic factors in cervical carcinoma, precancerous lesions of
the cervix uteri, and several other anogenital cancers in fe-
males and males (for reviews, see references 3 and 24). In
addition, about 26% of head and neck cancers are linked to
HPV infection (13). HPVs represent an extremely heteroge-
neous group of DNA viruses. Until now, more than 100 HPV
types have been identified and fully sequenced (9). Approxi-
mately 40 HPV types infecting the anogenital epithelium are
classified as either low risk (LR) or high risk (HR) on the basis
of their oncogenic potentials. A recent meta-analysis has des-
ignated 15 anogenital HPV types as HR, with an additional 3
HPV types designated as probable HR types (23).
Because of their biological properties, HPVs cannot easily
be grown in tissue culture, which makes the preparation of
antigens for the routine detection of HPV difficult (10). Fur-
thermore, serological assays, which detect HPV-specific anti-
bodies, cannot be used for diagnostic purposes, since these
antibodies are markers of a lifetime’s cumulative exposure to
HPV types (18). For diagnostic purposes, methods based on
the detection of HPV-specific nucleic acids are being used. In
addition, the typing of HPV isolates is done by means of
molecular biological methods (4).
Due to the large number of HPV types, methods for HPV
genotyping are difficult to standardize. Despite this fact, sev-
eral methods exist, and some of them are available commer-
cially. These HPV typing methods are mostly based on PCR
techniques with degenerate and/or consensus primers, fol-
lowed by an additional assay for the type-specific identification
of HPV. The most widely used PCR methods for the detection
of mucosal HPV types are based on primer set MY09-MY11
(21), GP5-GP6 (8), or SPF10 (19). All these primer sets
target the L1 region of the HPV genome. Several authors have
reported on the efficiency of amplification with these primers
as well as on a comparison of method performance (29, 34).
The GP5-GP6-based PCR system seems to be more sen-
sitive, more reliable, and reproducible than the MY09-MY11-
based PCR system (26). Additionally, primers PGMY09 and
PGMY11 (14), adapted from primers MY09 and MY11, detect
genital HPV types at a higher rate than primers MY09 and
MY11 (7). In general, HPV typing assays have good agreement
when a infection with a single HPV type is present, but agree-
ment is lower when infections with multiple HPV types are
present (12).
In this study, we evaluated the Roche Diagnostics linear
array (LA) HPV genotyping assay (5), the Innogenetics INNO-
LiPA (line probe assay [LiPA]) (20), and the noncommercial
GP5-GP6-based reverse line blot (GP-RLB) assay (35).
Additionally, an improved RLB assay was performed with the
broad-spectrum primers BSGP5 and BSGP6 (BS) de-
signed by Schmitt et al. (29), the BS-RLB assay. All of these
assays are well suited for population-based epidemiological
studies due to their easy and fast protocols. In this study, their
reliabilities were tested with HPV types less frequently present
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in individuals infected with multiple HPV types. To our knowl-
edge, this is the first study to compare the performance char-
acteristics of the most widely used HPV genotyping methods
with selected samples positive for low-prevalence HPV types.
MATERIALS AND METHODS
Sample collection. A total of 153 samples from two countries, Croatia and the
Czech Republic, were used for this study. The first set of samples consisted of 86
cervical DNA samples from Croatian women with histologically confirmed high-
grade squamous intraepithelial lesions (HSILs) (30). The samples were selected
from a collection of DNA samples previously collected and screened for HPV
DNA by the MY09-MY11-based PCR followed by type-specific PCR detection
of HPV types 6/11, 16, 18, 31, and 33 (15, 16). The selected samples were positive
by the MY09-MY11-based PCR but were not positive for HPV type 6, 11, 16, 18,
31, or 33 by type-specific primer-directed PCRs. In this study, the HPV types in
the selected samples were analyzed in parallel by the LA assay, LiPA, and the
GP- and BS-RLB assays.
The second set of samples consisted of 40 DNA samples from women from the
Czech Republic with HSILs and 27 samples from women with low-grade squa-
mous intraepithelial lesions (LSILs) (31). The samples were chosen on the basis
of typing by GP5-GP6-based PCR followed by the GP-RLB assay. Twenty
samples infected with single HPV types other than HPV types 6, 11, 16, 18, 31,
and 33 were selected. Additionally, 47 samples infected with multiple HPV types,
i.e., with more than one HPV type, were chosen irrespective of the HPV type 6,
11, 16, 18, 31, and 33 infection status. All samples were further tested by the LA
assay, LiPA, and the BS-RLB assay.
LiPA. The LiPA from Innogenetics uses biotinylated SPF10 PCR primers for
the amplification of a 65-bp region of the L1 gene of a broad spectrum of HPV
types (22). LiPA is capable of detecting 26 HPV types (Table 1). The assay was
performed according to the manufacturer’s protocol. Briefly, PCR was per-
formed in a total volume of 50 l containing 5 l of 10 PCR buffer, 200 M of
each deoxynucleoside triphosphate, 10 l primer mix, 2 mM MgCl2, 1.5 U
AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA), and 10
l (approximately 250 ng) of DNA. The DNA amplification was performed as
follows: 9 min of denaturation at 94°C; 40 cycles of 30 s of denaturation at 94°C,
45 s of annealing at 52°C, and 45 s of elongation at 72°C; and a final extension
for 5 min at 72°C. After amplification, 10 l of the PCR product was denatured
with the denaturation solution provided by the manufacturer and hybridized with
oligonucleotide probes immobilized on strips. After a stringent wash, hybrids
were visualized by the addition of streptavidin-alkaline phosphatase conjugate,
which binds to the biotinylated PCR primers, and a substrate (5-bromo-4-chloro-
3-indolylphosphate and nitroblue tetrazolium) that generates a purple precipi-
tate at the probe line.
LA assay. The LA assay from Roche Diagnostics uses the same principles as
LiPA, but with different PCR primers and oligonucleotide probes (5). The LA
assay uses the PGMY09-PGMY11 primer set, which amplifies a 450-bp fragment
of the L1 gene, and is capable of detecting 37 HPV types (Table 1). The assay was
performed according to the manufacturer’s instructions. Briefly, DNA was am-
plified in a total volume of 100 l containing 50 l (approximately 500 ng) of
sample DNA and 50 l of the master mixture provided by the manufacturer. The
amplification protocol was as follows: 9 min of denaturation at 95°C and 40 cycles
of 30 s of denaturation at 95°C, 1 min of annealing at 55°C, and 1 min of
elongation at 72°C, followed by a final extension for 5 min at 72°C. After
amplification, the whole PCR product was denatured and hybridized with oligo-
nucleotide probes immobilized on strips. After a stringent wash, the hybrids were
detected by the addition of streptavidin-horseradish peroxidase conjugate, which
binds to the biotinylated PCR primers, and a substrate (hydrogen peroxide and
3,3,5,5-tetramethylbenzidine) that generates a purple precipitate at the probe
line.
GP-RLB assay. The RLB hybridization assay enables the detection of HPV
and genotyping of 37 different HPV types (Table 1) (32). HPV detection was
performed by PCR with primer GP5 and with primer GP6 labeled with biotin
at the 5 end; these two primers generate a 150-bp fragment of the L1 gene. The
PCR was performed for 40 cycles, with each cycle consisting of 90 s of denatur-
ation at 94°C, 30 s of annealing at 38°C, and 80 s of elongation at 71°C. Defined
ramping times were used. The first cycle was preceded by a 5-min denaturation
step at 94°C, and the last cycle was followed by incubation at 71°C for 4 min.
Oligonucleotide probes with a 5-terminal amino group are covalently linked to
an activated negatively charged Biodyne C membrane with a miniblotter (MN45;
Immunetics, Boston, MA). For hybridization with PCR products, the membrane
is rotated 90° and samples are applied with a clean miniblotter so that the sample
lines are perpendicular to the probe lines. After a stringent wash, the membrane
is incubated with streptavidin-horseradish peroxidase conjugate. The conjugate
was visualized with an enhanced chemiluminescence detection liquid system
(Amersham) and by exposure of the membrane to LumiFilm (Roche) for 5 min.
BS-RLB assay. The BS-RLB analyses were performed as described above for
the GP-RLB assay, and the BS-based PCR was conducted as reported previously
(29). Briefly, eight additional forward primers and two additional 5-biotinylated
backward primers were added to the GP-PCR mixture: 200 nM of each forward
primer (including primer GP5), 400 nM of each backward primer (including
TABLE 1. Genotyping capabilities of the different assays used in
this study
Oncogenic
potentiala
and HPV type
Genotyping capability
LA assay
(Roche)
LiPA
(Innogenetics)
GP-RLB
assay
BS-RLB
assay
LR
6    
11    
34   
40    
42    
43   
44   
54    
55   
57  
61   
62 
64 
67 
69 
70    
71   
72   
74 
81   
83   
84   
IS39   
89   
HR
16    
18    
31    
33    
35    
39    
45    
51    
52 b   
56    
58    
59    
68  c  
73  c  
82   
Probably HR
26   
53    
66    
No. of detectable
HPV types
37 26 37 37
a According to Mun˜oz et al. (23).
b The LA assay cannot distinguish HPV-52 in samples containing HPV type
33, 35, or 58.
c LiPA cannot distinguish HPV types 68 and 73 from each other.
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the LA assay cannot exclude HPV type 52 when it is present
together with HPV type 33, 35, or 58 and LiPA cannot distin-
guish HPV types 68 and 73 from each other, as described in the
respective manufacturers’ protocols. For all samples for which
one of those types could not be clearly excluded due to the
presence of confounding types, the sample was considered
positive by the assay. This is a known limitation of both assays
and was not corrected for in any calculation in any way to make
the evaluation as objective as possible.
The prevalence of specific HPV types as detected by the LA
assay, LiPA, the GP-RLB assay, and the BS-RLB assay is
shown in Table 2. The frequencies of each HPV type when it
was found in each sample by at least one assay or all four assays
are also indicated in Table 2. The most common HPV type in
the samples analyzed was HPV type 58 (HPV-58), which was
identified by all four assays in 21 of the 153 (13.7%) cases. The
next most abundant HPV types were HPV-16, found by all
assays in 17 (11.1%) samples, and HPV-51, found by all as-
says in 16 (10.5%) samples. HPV types 52 and 66 were both
found in 15 of 153 (9.8%) cases. HPV types 45, 56, and 31 were
found in 14 of 153 (9.2%), 13 of 153 (8.5%), and 9 of 153
(5.9%) samples, respectively. The frequency of other HPV
types was below 5%. HPV types 57, 64, 69, and 74 were not
found in any of the samples tested by any assay. The overall
typing capability of the LA assay was the best (99.3%), fol-
lowed by the BS-RLB assay (97.4%), LiPA (95.4%), and the
GP-RLB assay (94.8%) (Table 2).
By means of the LA assay, LiPA, the GP-RLB assay, and the
BS-RLB assay, HPV types detectable by all four assays (assay
common types) were found in 94.1%, 92.8%, 88.2%, and
94.1% of the 153 samples, respectively; and multiple infections
were detected by the four assays in 55.6%, 37.3%, 43.1%, and
52.9% samples, respectively (Table 3). The majority of infec-
tions with multiple HPV types found were double infections:
58.8%, 54.4%, 66.7%, and 60.5% by the LA assay, LiPA, the
GP-RLB assay, and the BS-RLB assay, respectively. The high-
est number of HPV types in a single sample was identified by
the LA assay, with a mean of 2.5 HPV types per sample (range,
1 to 8 HPV types per sample); the BS-RLB assay detected a
mean of 2 HPV types per sample (range, 1 to 6 HPV types per
sample); and 1.7 HPV types per sample were identified by both
LiPA and the GP-RLB assay (ranges, 1 to 6 HPV types per
sample for LiPA and 1 to 4 HPV types per sample for the
GP-RLB assay). Fisher’s exact test showed that for assay com-
mon HPV types, the LA and BS-RLB assays were the most
sensitive in detecting infections with multiple HPV types
(LiPA versus LA assay, P  0.0015; LiPA versus BS-RLB
assay, P 0.0067). The GP-RLB assay detected fewer multiple
infections than the LA assay (P  0.0940) and the BS-RLB
assay (P  0.2320), but this was not significant in either case.
There was no significant difference between the LA and the
BS-RLB assays (P  0.7206) or between LiPA and the GP-
RLB assay (P  0.1488).
Figure 1 compares the frequencies of the HR and the LR
HPV types detected by the four assays. The HPV types are
listed in decreasing frequency of detection by any assay. Figure
1 indicates the assay common HPV types for which Friedman’s
test showed a statistically significant discrepancy between the
assays tested. These were for HPV types 16 (P  0.009), 39
(P  0.0097), 42 (P  0.0001), 51 (P  0.0044), 52 (P 
0.00001), 53 (P 0.00001), 54 (P 0.006), 56 (P 0.0004), 58
(P  0.0007), 59 (P  0.0293, 68 (P  0.0009), and 73 (P 
0.062).
The interrate agreement ( value) and the 95% confidence
interval were calculated for all assay pairs for all HPV types (data
not shown). In some cases, it was not possible to calculate the 
value, as some HPV types were not present in either of the pair
of assays or no cases of that HPV type were found in a particular
pair. The agreement between assays was calculated as the average
agreement in detecting all HPV types common for that assay pair.
The best assay pair agreement was observed between the LA
assay and LiPA (average  value  0.68), followed by the GP-
RLB and the BS-RLB assays (average  value  0.67), the LA
and the BS-RLB assays (average  value  0.62), and LiPA
and the BS-RLB assay (average  value  0.66), all of which
indicate good strengths of agreement. Moderate agreement
strengths with average  values of 0.54 and 0.57 were obtained
for the LA and the GP-RLB assays and for LiPA and the
GP-RLB assay, respectively (data not shown).
The strength of interassay agreement for each HPV type was
calculated as an average of all interassay pair  values for a
particular type. It was calculated only for assay common types.
Figure 2 presents these results for each HPV type in decreas-
ing order of strength of agreement. HPV-35 had the greatest
average  value (0.94) and, along with HPV types 11, 45, 51, 56,
58, 66, and 70, fits into the very good agreement group (range
of  values for these types, 0.82 to 0.94). The interassay agree-
ment for HPV types 16, 18, 31, 33, 39, 42, and 68 was good
(range of  values, 0.61 to 0.79). Moderate interassay agree-
ment (range of  values, 0.54 to 0.58) was obtained for HPV
types 6, 52, 53, 59, and 73. The assays had a fair strength of
interassay agreement for HPV type 54 ( value, 0.27). The
interassay agreement for HPV-40 was worse than chance, hav-
ing an average  value of	0.002. For the other HPV types, the
interassay agreement could not be determined.
Table 4 summarizes the agreement between assays for the
typing of assay common types in cases of single versus multiple
infections. Thus, in 71.8% cases of single infections, all four
assays agreed on the types present, while in cases of multiple
TABLE 3. Types of HPV infections present in samples, identified
by LA assay (Roche), LiPA (Innogenetics), GP-RLB assay,
and BS-RLB assay, and common to all four assays
No. of HPV
typesa
No. (%) of cases detected by:
LA assayb LiPAc GP-RLBassay
BS-RLB
assay
Any 144 (94.1) 142 (92.8) 135 (88.2) 144 (94.1)
Single 59 (38.6) 85 (55.6) 69 (45.1) 63 (41.2)
Multiple 85 (55.6) 57 (37.3) 66 (43.1) 81 (52.9)
Two 50 (32.7) 31 (20.3) 44 (28.8) 49 (32.0)
Three 16 (10.5) 17 (11.1) 18 (11.8) 18 (11.8)
Four 11 (7.2) 7 (4.6) 4 (2.6) 10 (6.5)
Five 7 (4.6) 1 (0.7) 0 (0) 4 (2.6)
Six 1 (0.7) 1 (0.7) 0 (0) 0 (0)
None 9 (5.9) 11 (7.2) 18 (11.8) 9 (5.9)
a HPV types present in all four assays: HPV types 6, 11, 16, 18, 31, 33, 35, 39,
40, 42, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, and 73.
b The LA assay cannot distinguish HPV-52 in samples containing HPV type
33, 35, or 58.
c LiPA cannot distinguish HPV types 68 and 73.
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infections, complete agreement was found in only 6.2% cases,
and in 93.8% of samples with multiple infections, partial agree-
ment was found between the four assays. Agreement was con-
sidered complete if all four assays gave completely identical
results for the sample in question on the basis of assay common
types. On the other hand, agreement was considered partial
when any two or more assays agreed on one or more of the
HPV types present in a particular sample. The values were
comparable when we evaluated all types identifiable by any
assay and not only assay common types (data not shown).
DISCUSSION
The reason for this study was the lack of published data on
comparisons of test performances for low-prevalence HPV
types.
All four assays, the LA assay, LiPA, the GP-RLB assay, and
the BS-RLB assay, evaluated in this study enabled the detec-
tion of up to 16 HR or possible HR HPV types, depending on
the assay, which justifies their use for epidemiological and
clinical studies. Additionally, the LA assay and both RLB as-
says also allowed the detection and typing of more LR HPV
types than LiPA did (Table 1). This advantage of the LA,
GP-RLB, and BS-RLB assays can be interesting for epidemi-
ological studies; i.e., some low-abundance LR types might be
shown to be associated with neoplastic changes in cervical
squamous cells. For instance, in our study LR HPV-70 as a
single infection was found unexpectedly often in HSIL samples
(data not shown); larger epidemiological studies are necessary
to possibly classify it among the HR HPV types.
Considering all types that an assay is able to detect, the LA
assay was the most sensitive, as it was able to reveal the HPV
type present in all except one sample. For the BS-RLB assay,
LiPA, and the GP-RLB assay, the numbers of samples in which
HPV was detected were slightly lower for assay common HPV
types only.
The highest number of HPV types in a single sample was
identified by the LA assay, followed by the BS-RLB assay,
LiPA, and the GP-RLB assay. This could indicate the low
sensitivity of LiPA and the GP-RLB assay or an unspecific
amplification and/or hybridization by the LA and BS-RLB
assays. For assay common HPV types, the LA and BS-RLB
assays were the two assays that detected multiple HPV infec-
tions (more than one HPV type in a sample) with the most
sensitivity, while the least sensitive assay was LiPA. However,
we can hypothesize that these data show that LiPA is the most
specific assay, while the LA and BS-RLB assays reveal a cer-
tain level of unspecific amplification and/or hybridization. This
large difference in multiple HPV infections identified could
not be attributed to the fact that the RLB and LA assays tested
for more HPV types than LiPA did, as only assay common
types were considered. This observation was in disagreement
with the results of Gillio-Tos et al. (12), who have reported that
FIG. 1. Frequencies of detection of HR (A) and LR (B) HPV types by the LA assay, LiPA, the GP-RLB assay, and/or the BS-RLB assay in
153 selected samples; HPV types are sorted by decreasing average frequency as detected by any of the assays; stars, significant differences
(Friedman test) between assays for a particular HPV type; *, HPV types not included in all four assays (Table 1); the LA assay cannot distinguish
HPV-52 in samples containing HPV type 33, 35, or 58; and LiPA cannot distinguish HPV types 68 and 73 from each other.
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LiPA is more sensitive than the GP-RLB and Amplisense
assays.
The strength of the interassay agreement for each assay
common type was calculated as the average  value of all assay
pair combinations for that type (data not shown). It is inter-
esting to note that only good agreement and not a perfect
strength of agreement was found for the most common HR
HPV types (types 16, 18, 31, and 33). This observation suggests
a possible problem for accurate typing. Furthermore, signifi-
cant differences were observed in 12 of 22 HPV types common
to all four assays. For HPV-58, differences arose from the
lower number of positive samples detected by the LA assay and
LiPA compared with the number of positive samples detected
by both versions of the RLB assay, although the total agree-
ment for HPV-58 still indicated very good agreement. The
same observation was found for HPV types 56 and 51; HPV-51
was detected the least often by the GP-RLB assay and the most
often by LiPA, while HPV-56 was found the least often by
LiPA (Table 2; Fig. 1).
HPV-45 was among the HPV types for which the assays had
very good agreement, and no significant discrepancy was ob-
served; it was detected only slightly less often by LiPA.
Significant interassay variations were revealed for HPV
types 39, 42, and 68, as their average  values indicated only
good agreement. For HPV-39, the GP-RLB assay gave the
fewest number of positive samples. In the case of HPV-42, the
BS-RLB assay gave the most positive results and LiPA missed
most of the positive samples. The low sensitivity of LiPA for
HPV-42 was described previously (34). For HPV-68, LiPA
gave a great overestimation, as it failed to discriminate HPV 68
and 73, but even with this known limitation (27), the agree-
ment between assays was quite good. Nevertheless, this over-
estimation will pose problems if LiPA is used alone in epide-
miological studies and especially if these two types have
different prevalences in the population studied.
Differences between assays for the typing of the most com-
mon LR HPV types, types 6 and 11, were not significant for
either type; but the strengths in agreement between the assays
were very different for these types. Since our sample pool was
artificially depleted of these types, the result is of limited value.
In contrast, the highest strength of interassay agreement was
found for HPV types 35, 66, and 70, indicating that these types
are almost equally detected by all four assays.
Moderate agreement was also observed for HPV types 52,
53, 59, and 73. This might pose a bigger problem, as all these
types are HR HPV types, and for each of them the discrepancy
was significant. For HPV-52, the LA assay grossly overesti-
mated its presence, as it cannot distinguish it from HPV type
33, 35, or 58 (6). As a consequence, HPV-52 was the most
common type found by this assay. All other assays detected
HPV-52 less often, with the GP-RLB assay having the lowest
rate of detection of this type. We stress again that this over-
estimation is due to the LA assay design and is a known
TABLE 4. Overview of interassay agreement between LA assay,
LiPA, GP-RLB assay, and BSP-RLB assay regarding
their capability for HPV type identification
Type of
infection
HPV types present in all
four assaysa
Agreementb
No. (%) of
samples
No. of cases
(% of group)
All 152 (99.3) 35 (23.0) Complete
111 (73.0) Partial
6 (3.9) None
Single 39 (25.5) 28 (71.8) Complete
5 (12.8) Partial
6 (15.4) None
Multiple 113 (73.9) 7 (6.2) Complete
106 (93.8) Partial
0 None
a The LA assay cannot distinguish HPV-52 in samples containing HPV type
33, 35, or 58; and LiPA cannot distinguish HPV types 68 and 73. One sample
(0.7%) had no HPV type present by all four assays.
b Complete, identical HPV types were simultaneously detected by all four
assays in one sample; partial, one or more HPV types were in common by two or
more assays; none, different HPV types were detected by all four assays.
FIG. 2. Average  value of one-by-one interassay agreement mea-
surements for each HPV type present by the LA assay, LiPA, the
GP-RLB assay, and the BSP-RLB assay. *, HPV types for which
significant differences were observed; the LA assay cannot distinguish
HPV-52 in samples containing HPV type 33, 35, or 58; LiPA cannot
distinguish HPV types 68 and 73.
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limitation of this assay. Until this limitation is overcome, sam-
ples indicated to contain HPV-52 by the LA assay should be
viewed with greater caution in epidemiological studies. On the
other hand, when clinical samples are evaluated for diagnostic
purposes, this probe cross-reactivity is not as important, as the
patient has already been found to be infected with an HR HPV
type (type 33, 35, or 58) and, regardless of HPV-52 positivity,
should be considered at higher risk of disease. The difference
observed for HPV-53 had to be attributed primarily to the fact
that the GP-RLB assay failed to detect this type, as has been
shown earlier by Qu et al. (25). In the case of HPV-73, we
expected the same problem with LiPA that was encountered
with HPV-68. However, when the LiPA findings for HPV-73
are compared with the LA assay findings, LiPA slightly under-
estimated this type’s presence, while the BS-RLB assay greatly
underestimated its presence in comparison with the prevalence
of this type detected by LiPA or the LA assay.
The only HPV type which showed a fair strength of interas-
say agreement was HPV-54. In this case, LiPA completely
failed to detect it, while the GP-RLB assay found it less often
than the remaining two assays.
HPV-40, which can be typed by all four assays, was detected
in only two cases by the LA assay and once by LiPA, but not in
the concordant sample (Table 2). Even though the number of
HPV-40-positive samples was very low, this result suggests that
the primer and probes used in both RLB assays should be
reevaluated and/or the assays should be compared by use of a
larger pool of HPV-40-positive samples.
Complete agreement between assays in detecting assay com-
mon HPV types in single and multiple infections was the high-
est in cases of single infections, but so was complete disagree-
ment. In cases of multiple infections, partial agreement
dominated; and because of this, when all types of infections
were combined, partial agreement was again the most com-
mon. This clearly indicates that the LA assay, LiPA, the GP-
RLB assay, and the BS-RLB assay do not in reality give the
same answer when they are used to test samples infected with
multiple HPV types; and when such infections are common in
the study population, this greatly affects overall assay agree-
ment. On the other hand, the assays are not likely to com-
pletely disagree (Table 4). Similar results were observed by
Gillio-Tos et al. (12), who compared the GP-RLB assay, LiPA,
and the Amplisense assay and reported high levels of assay
concordance for single infections but limited concordance for
multiple infections. This is probably due to the differences in
the affinities of the primer sets for the different HPV types. In
addition, the concentration of a particular HPV type in the
sample plays a role. In our experience, the use of a combina-
tion of typing methods only with knowledge of the limitation of
each of them allows the unambiguous HPV typing, but the cost
is unacceptable for routine settings.
When the results of similar studies are compared to our
results, both van Hamont et al. (36) and van Doorn et al. (35),
who compared only the LA assay and LiPA, have found these
two assays to be highly comparable for the detection of assay
common HPV types. While in our study these assays showed a
higher average  value than the other assay pairs, we found
their strengths of agreement to be good, although not very
good. Contrary to our study, both of those studies were de-
signed not to be challenging for the assays and usually analyzed
samples with normal cytologies, a relatively small number of
samples infected with multiple HPV types, and a normal dis-
tribution of HPV types. In our study, we wanted to evaluate the
assays under more difficult conditions when low-prevalence
and/or multiple HPV types were present. In such a sample
pool, there is a strong possibility that different HPV types
compete for the PCR reagents, and thus, especially when the
HPV types are not present in the same amounts, the levels of
the PCR amplicons of one type might remain below the de-
tection limit of the assay.
Some authors (1, 2, 22, 28, 33) have found infections with
multiple HPV types to be associated with a higher risk of
progressive disease or cervical neoplasia, while some (22) have
described fewer multiple infections in women with cervical
cancer or a decreasing number of HPV types with an increas-
ing severity of disease (34). In addition, some authors have
reported no increased risk of cervical intraepithelial neoplasia
or cervical cancer among women with multiple HPV infections
than among women with single HPV infections (3, 17), while
others have found a discrepant result (11). On the basis of our
results, it is clear that to strongly link infection with multiple
HPV types with disease progression, the choice of typing assay
is essential.
In this study, we have considered the ability of each of the
four assays tested to detect a wide spectrum of less prevalent
HPV types. We focused on interassay agreement, both overall
and type specific, in cases with single and/or multiple HPV
infections. Our results showed a large variability in the ability
of a particular assay to detect different HPV types. The LA and
BS-RLB assays found larger numbers of cases positive for
multiple types than the two other assays did. The lowest capa-
bility of detecting multiple infections was observed for LiPA.
The interassay agreement was moderate for single infections
and poor for multiple infections. The use of only one assay in
epidemiological and clinical studies might lead to biased con-
clusions. Therefore, a universally evaluated and agreed upon
HPV typing assay or a combination of current assays is needed
for possible clinical applications, and knowledge of their limi-
tations is advised.
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